Symbols / OSUR
OSUR Chart
About
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic and specimen collection devices and products in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; and Colli-Pee collection devices for the volumetric collection of void urine samples. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, the company offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. The company sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, nutrition, companion animal, and environmental markets. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Instruments & Su | Market Cap | 206.25M |
| Enterprise Value | -724.45K | Income | -60.24M | Sales | 125.70M |
| Book/sh | 5.01 | Cash/sh | 3.02 | Dividend Yield | — |
| Payout | 0.00% | Employees | 501 | IPO | — |
| P/E | — | Forward P/E | -5.18 | PEG | — |
| P/S | 1.64 | P/B | 0.56 | P/C | — |
| EV/EBITDA | 0.01 | EV/Sales | -0.01 | Quick Ratio | 5.98 |
| Current Ratio | 7.03 | Debt/Eq | 3.72 | LT Debt/Eq | — |
| EPS (ttm) | -0.81 | EPS next Y | -0.54 | EPS Growth | — |
| Revenue Growth | -32.10% | Earnings | 2026-02-25 | ROA | -8.80% |
| ROE | -15.30% | ROIC | — | Gross Margin | 40.61% |
| Oper. Margin | -58.02% | Profit Margin | -47.92% | Shs Outstand | 71.73M |
| Shs Float | 63.67M | Short Float | 5.55% | Short Ratio | 6.66 |
| Short Interest | — | 52W High | 4.22 | 52W Low | 2.08 |
| Beta | 0.91 | Avg Volume | 588.75K | Volume | 356.56K |
| Target Price | $4.50 | Recom | None | Prev Close | $2.75 |
| Price | $2.82 | Change | 2.55% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$4.50
Mean price target
2. Current target
$2.82
Latest analyst target
3. DCF / Fair value
$-1.03
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.82
Low
$3.00
High
$6.00
Mean
$4.50
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-12 | main | Stephens & Co. | Equal-Weight → Equal-Weight | $3 |
| 2025-05-19 | main | Evercore ISI Group | In-Line → In-Line | $3 |
| 2025-05-08 | main | Evercore ISI Group | In-Line → In-Line | $3 |
| 2024-08-07 | main | Evercore ISI Group | In-Line → In-Line | $5 |
| 2024-07-02 | main | Evercore ISI Group | In-Line → In-Line | $5 |
| 2024-05-13 | main | JP Morgan | Neutral → Neutral | $6 |
| 2024-04-04 | main | Evercore ISI Group | In-Line → In-Line | $7 |
| 2024-02-29 | main | JP Morgan | Neutral → Neutral | $7 |
| 2023-12-11 | main | Citigroup | Buy → Buy | $9 |
| 2023-11-08 | main | JP Morgan | Neutral → Neutral | $5 |
| 2023-07-17 | main | Stephens & Co. | Equal-Weight → Equal-Weight | $5 |
| 2022-05-11 | main | Citigroup | — → Buy | $10 |
| 2022-02-24 | main | Citigroup | — → Buy | $12 |
| 2021-09-22 | down | Raymond James | Outperform → Market Perform | — |
| 2021-08-04 | main | Raymond James | — → Outperform | $13 |
| 2021-06-28 | main | Raymond James | — → Outperform | $11 |
| 2021-05-06 | main | Raymond James | — → Outperform | $12 |
| 2020-08-21 | init | Evercore ISI Group | — → Outperform | $22 |
| 2020-08-10 | init | JP Morgan | — → Neutral | $18 |
| 2020-08-10 | init | Citigroup | — → Buy | $18 |
- OraSure Technologies (NASDAQ:OSUR) Stock Price Crosses Above Two Hundred Day Moving Average - Here's What Happened - MarketBeat hu, 12 Feb 2026 08
- Revenues Working Against OraSure Technologies, Inc.'s (NASDAQ:OSUR) Share Price Following 25% Dive - simplywall.st Fri, 14 Nov 2025 08
- Outside investor seeks two board seats at OraSure Technologies - Stock Titan hu, 15 Jan 2026 08
- Will OSUR stock attract ESG investors - Dollar Strength & Daily Entry Point Trade Alerts - mfd.ru Fri, 20 Feb 2026 21
- OraSure Technologies: An Asymmetric Bet (NASDAQ:OSUR) - Seeking Alpha Mon, 28 Jul 2025 07
- The past five years for OraSure Technologies (NASDAQ:OSUR) investors has not been profitable - Yahoo Finance Mon, 06 Oct 2025 07
- OraSure Technologies (OSUR) Expected to Announce Earnings on Wednesday - MarketBeat Wed, 18 Feb 2026 07
- OraSure Technologies (NASDAQ:OSUR investor five-year losses grow to 80% as the stock sheds US$22m this past week - simplywall.st Wed, 05 Nov 2025 08
- Hedge Fund Reportedly Prepares To Launch Board Fight At OraSure Technologies: Retail Investors Believe It’s Good News - Stocktwits ue, 09 Sep 2025 07
- Market Review: What is the dividend yield of OSUR - Market Performance Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn ue, 24 Feb 2026 16
- Balance Sheet - Intellectia AI Sat, 14 Feb 2026 08
- OraSure Files for FDA Review of Molecular Self-Test & Colli-Pee Device - Nasdaq ue, 06 Jan 2026 08
- OraSure Technologies (OSUR) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance Wed, 05 Nov 2025 08
- Altai Capital nominates two directors to OraSure's board (update) (OSUR:NASDAQ) - Seeking Alpha hu, 15 Jan 2026 08
- OraSure Technologies, Inc. (NASDAQ:OSUR) Analysts Are Pretty Bullish On The Stock After Recent Results - simplywall.st Fri, 08 Aug 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10286 | 25304 | — | Stock Award(Grant) at price 2.46 per share. | KENNY JOHN P | Director | — | 2025-12-17 00:00:00 | D |
| 1 | 2100 | 4982 | — | Purchase at price 2.37 per share. | GAGLIANO NANCY J | Director | — | 2025-11-28 00:00:00 | D |
| 2 | 34632 | — | — | Stock Award(Grant) at price 0.00 per share. | BOYD STEVEN KYLE | Director | — | 2025-10-28 00:00:00 | D |
| 3 | 6118 | 20000 | — | Stock Award(Grant) at price 3.27 per share. | KENNY JOHN P | Director | — | 2025-09-24 00:00:00 | D |
| 4 | 6657 | 20026 | — | Stock Award(Grant) at price 3.01 per share. | KENNY JOHN P | Director | — | 2025-06-24 00:00:00 | D |
| 5 | 335710 | — | — | Stock Award(Grant) at price 0.00 per share. | EGLINTON MANNER CARRIE | Chief Executive Officer | — | 2025-06-04 00:00:00 | D |
| 6 | 71017 | — | — | Stock Award(Grant) at price 0.00 per share. | MARMORA LELIO | Director | — | 2025-05-14 00:00:00 | D |
| 7 | 71017 | — | — | Stock Award(Grant) at price 0.00 per share. | GAGLIANO NANCY J | Director | — | 2025-05-14 00:00:00 | D |
| 8 | 71017 | — | — | Stock Award(Grant) at price 0.00 per share. | MCMAHON ROBERT W | Director | — | 2025-05-14 00:00:00 | D |
| 9 | 71017 | — | — | Stock Award(Grant) at price 0.00 per share. | ASPINALL MARA G | Director | — | 2025-05-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -922.32K | -493.58K | -3.55M | 400.95K |
| TaxRateForCalcs | 0.21 | 0.05 | 0.21 | 0.27 |
| NormalizedEBITDA | -9.16M | 75.08M | 27.21M | -639.00K |
| TotalUnusualItems | -4.39M | -10.73M | -16.91M | 1.49M |
| TotalUnusualItemsExcludingGoodwill | -4.39M | -10.73M | -16.91M | 1.49M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -19.50M | 53.66M | -17.13M | -23.00M |
| ReconciledDepreciation | 10.31M | 20.94M | 15.54M | 12.49M |
| ReconciledCostOfRevenue | 106.44M | 233.82M | 239.04M | 116.07M |
| EBITDA | -13.55M | 64.35M | 10.29M | 846.00K |
| EBIT | -23.86M | 43.41M | -5.24M | -11.65M |
| NormalizedIncome | -16.03M | 63.89M | -3.77M | -24.08M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -19.50M | 53.66M | -17.13M | -23.00M |
| TotalExpenses | 209.69M | 362.06M | 392.72M | 245.32M |
| TotalOperatingIncomeAsReported | -28.25M | 32.68M | -22.16M | -10.16M |
| DilutedAverageShares | 74.43M | 74.39M | 72.50M | 71.98M |
| BasicAverageShares | 74.43M | 73.35M | 72.50M | 71.98M |
| DilutedEPS | -0.26 | 0.72 | -0.25 | -0.32 |
| BasicEPS | -0.26 | 0.73 | -0.25 | -0.32 |
| DilutedNIAvailtoComStockholders | -19.50M | 53.66M | -17.13M | -23.00M |
| NetIncomeCommonStockholders | -19.50M | 53.66M | -17.13M | -23.00M |
| NetIncome | -19.50M | 53.66M | -17.13M | -23.00M |
| NetIncomeIncludingNoncontrollingInterests | -19.50M | 53.66M | -17.13M | -23.00M |
| NetIncomeContinuousOperations | -19.50M | 53.66M | -17.13M | -23.00M |
| EarningsFromEquityInterestNetOfTax | -1.70M | 0.00 | 0.00 | |
| TaxProvision | 1.80M | 2.60M | 1.46M | 13.71M |
| PretaxIncome | -16.00M | 56.26M | -15.68M | -9.29M |
| OtherIncomeExpense | 7.86M | 12.84M | -10.43M | 2.36M |
| OtherNonOperatingIncomeExpenses | 12.25M | 23.57M | 6.48M | 872.00K |
| SpecialIncomeCharges | -4.39M | -10.73M | -16.91M | 1.49M |
| GainOnSaleOfBusiness | 0.00 | |||
| ImpairmentOfCapitalAssets | 4.39M | 10.83M | 17.10M | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | -99.00K | -188.00K | -1.49M |
| OperatingIncome | -23.86M | 43.41M | -5.24M | -11.65M |
| OperatingExpense | 103.25M | 128.24M | 153.68M | 129.25M |
| ResearchAndDevelopment | 26.05M | 33.73M | 36.24M | 34.17M |
| SellingGeneralAndAdministration | 77.20M | 94.51M | 117.44M | 95.08M |
| SellingAndMarketingExpense | 30.99M | 36.32M | 49.24M | 44.75M |
| GeneralAndAdministrativeExpense | 46.22M | 58.19M | 68.21M | 50.33M |
| OtherGandA | 46.22M | 58.19M | 68.21M | 50.33M |
| GrossProfit | 79.39M | 171.65M | 148.44M | 117.60M |
| CostOfRevenue | 106.44M | 233.82M | 239.04M | 116.07M |
| TotalRevenue | 185.83M | 405.47M | 387.48M | 233.67M |
| OperatingRevenue | 184.61M | 402.22M | 378.05M | 226.90M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 74.60M | 73.53M | 72.73M | 72.07M |
| ShareIssued | 74.60M | 73.53M | 72.73M | 72.07M |
| TotalDebt | 14.60M | 13.50M | 12.55M | 12.27M |
| TangibleBookValue | 352.57M | 393.77M | 317.63M | 325.91M |
| InvestedCapital | 410.34M | 430.67M | 364.43M | 380.53M |
| WorkingCapital | 299.74M | 346.92M | 256.13M | 231.24M |
| NetTangibleAssets | 352.57M | 393.77M | 317.63M | 325.91M |
| CapitalLeaseObligations | 14.60M | 13.50M | 12.55M | 12.27M |
| CommonStockEquity | 410.34M | 430.67M | 364.43M | 380.53M |
| TotalCapitalization | 410.34M | 430.67M | 364.43M | 380.53M |
| TotalEquityGrossMinorityInterest | 410.34M | 430.67M | 364.43M | 380.53M |
| StockholdersEquity | 410.34M | 430.67M | 364.43M | 380.53M |
| GainsLossesNotAffectingRetainedEarnings | -24.36M | -14.94M | -18.43M | -10.08M |
| OtherEquityAdjustments | -24.36M | -14.94M | -18.43M | -10.08M |
| RetainedEarnings | -103.43M | -83.93M | -137.59M | -120.45M |
| AdditionalPaidInCapital | 538.13M | 529.54M | 520.45M | 511.06M |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 69.32M | 52.17M | 79.75M | 80.46M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 35.84M | 12.64M | 10.69M | 12.39M |
| OtherNonCurrentLiabilities | 23.40M | 696.00K | 680.00K | 1.00M |
| NonCurrentDeferredLiabilities | 0.00 | 554.00K | 408.00K | 2.23M |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 554.00K | 408.00K | 2.23M |
| LongTermDebtAndCapitalLeaseObligation | 12.43M | 11.39M | 9.60M | 9.15M |
| LongTermCapitalLeaseObligation | 12.43M | 11.39M | 9.60M | 9.15M |
| CurrentLiabilities | 33.48M | 39.54M | 69.06M | 68.06M |
| OtherCurrentLiabilities | 5.22M | 3.98M | 5.52M | 4.75M |
| CurrentDeferredLiabilities | 2.96M | 1.56M | 2.27M | 2.94M |
| CurrentDeferredRevenue | 2.96M | 1.56M | 2.27M | 2.94M |
| CurrentDebtAndCapitalLeaseObligation | 2.17M | 2.12M | 2.94M | 3.12M |
| CurrentCapitalLeaseObligation | 2.17M | 2.12M | 2.94M | 3.12M |
| PayablesAndAccruedExpenses | 23.13M | 31.88M | 58.33M | 57.26M |
| CurrentAccruedExpenses | 13.62M | 17.48M | 18.79M | 27.01M |
| Payables | 9.51M | 14.40M | 39.54M | 30.25M |
| TotalTaxPayable | 1.34M | 1.25M | 1.52M | 2.23M |
| AccountsPayable | 8.17M | 13.15M | 38.02M | 28.02M |
| TotalAssets | 479.66M | 482.85M | 444.18M | 460.99M |
| TotalNonCurrentAssets | 146.44M | 96.39M | 118.99M | 161.68M |
| OtherNonCurrentAssets | 1.53M | 1.22M | 1.09M | 5.07M |
| NonCurrentDeferredAssets | 156.00K | 0.00 | ||
| NonCurrentDeferredTaxesAssets | 156.00K | 0.00 | ||
| InvestmentsAndAdvances | 28.30M | 0.00 | 0.00 | 17.01M |
| LongTermEquityInvestment | 28.30M | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 57.77M | 36.90M | 46.80M | 54.62M |
| OtherIntangibleAssets | 17.43M | 1.21M | 11.69M | 14.34M |
| Goodwill | 40.33M | 35.70M | 35.10M | 40.28M |
| NetPPE | 58.69M | 58.27M | 71.11M | 84.98M |
| AccumulatedDepreciation | -65.92M | -85.14M | -69.88M | -61.16M |
| GrossPPE | 124.61M | 143.41M | 140.99M | 146.14M |
| ConstructionInProgress | 9.62M | 9.20M | 11.12M | 21.21M |
| OtherProperties | 13.59M | 12.85M | 11.69M | 11.55M |
| MachineryFurnitureEquipment | 64.14M | 85.64M | 81.47M | 76.85M |
| BuildingsAndImprovements | 36.15M | 34.61M | 35.58M | 35.42M |
| LandAndImprovements | 1.12M | 1.12M | 1.12M | 1.12M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 333.22M | 386.46M | 325.19M | 299.31M |
| OtherCurrentAssets | 3.49M | 2.23M | 41.57M | 39.87M |
| PrepaidAssets | 3.96M | 6.04M | 6.27M | 7.94M |
| Inventory | 34.20M | 47.61M | 95.70M | 53.14M |
| OtherInventories | 1.00K | |||
| FinishedGoods | 16.77M | 24.99M | 50.92M | 17.72M |
| WorkInProcess | 420.00K | 1.90M | 2.33M | 2.25M |
| RawMaterials | 17.00M | 20.73M | 42.45M | 33.17M |
| Receivables | 23.82M | 40.17M | 70.80M | 45.32M |
| AccountsReceivable | 23.82M | 40.17M | 70.80M | 45.32M |
| AllowanceForDoubtfulAccountsReceivable | -774.00K | -1.22M | -2.37M | -3.42M |
| GrossAccountsReceivable | 24.59M | 41.39M | 73.16M | 48.74M |
| CashCashEquivalentsAndShortTermInvestments | 267.76M | 290.41M | 110.85M | 153.04M |
| OtherShortTermInvestments | 0.00 | 26.87M | 36.28M | |
| CashAndCashEquivalents | 267.76M | 290.41M | 83.98M | 116.76M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | 23.58M | 131.28M | -111.11M | -83.50M |
| RepurchaseOfCapitalStock | -3.55M | -1.90M | -2.25M | -2.11M |
| RepaymentOfDebt | -842.00K | -1.34M | -1.38M | -686.00K |
| IssuanceOfCapitalStock | 0.00 | 0.00 | ||
| CapitalExpenditure | -3.80M | -10.30M | -63.91M | -48.12M |
| EndCashPosition | 267.76M | 290.41M | 83.98M | 116.76M |
| BeginningCashPosition | 290.41M | 83.98M | 116.76M | 160.80M |
| EffectOfExchangeRateChanges | -6.82M | 1.71M | -2.84M | -340.00K |
| ChangesInCash | -15.83M | 204.71M | -29.95M | -43.70M |
| FinancingCashFlow | -4.18M | -3.02M | -3.83M | -2.82M |
| CashFlowFromContinuingFinancingActivities | -4.18M | -3.02M | -3.83M | -2.82M |
| NetOtherFinancingCharges | -46.00K | -208.00K | -264.00K | |
| ProceedsFromStockOptionExercised | 214.00K | 269.00K | 15.00K | 246.00K |
| NetCommonStockIssuance | -3.55M | -1.90M | -2.25M | -2.11M |
| CommonStockPayments | -3.55M | -1.90M | -2.25M | -2.11M |
| CommonStockIssuance | 0.00 | 0.00 | ||
| NetIssuancePaymentsOfDebt | -842.00K | -1.34M | -1.38M | -686.00K |
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtPayments | 0.00 | |||
| NetLongTermDebtIssuance | -842.00K | -1.34M | -1.38M | -686.00K |
| LongTermDebtPayments | -842.00K | -1.34M | -1.38M | -686.00K |
| InvestingCashFlow | -39.03M | 66.15M | 21.09M | -5.50M |
| CashFlowFromContinuingInvestingActivities | -39.03M | 66.15M | 21.09M | -5.50M |
| NetOtherInvestingChanges | 48.67M | 60.45M | 513.00K | |
| NetInvestmentPurchaseAndSale | -192.00K | 27.79M | 24.54M | 42.10M |
| SaleOfInvestment | 53.05M | 102.44M | 47.41M | 67.92M |
| PurchaseOfInvestment | -53.24M | -74.65M | -22.87M | -25.82M |
| NetBusinessPurchaseAndSale | -35.04M | 0.00 | 0.00 | 0.00 |
| SaleOfBusiness | 0.00 | |||
| PurchaseOfBusiness | -35.04M | 0.00 | 0.00 | 0.00 |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | ||
| PurchaseOfIntangibles | 0.00 | 0.00 | ||
| NetPPEPurchaseAndSale | -3.80M | -10.30M | -63.91M | -48.12M |
| PurchaseOfPPE | -3.80M | -10.30M | -63.91M | -48.12M |
| OperatingCashFlow | 27.37M | 141.58M | -47.20M | -35.38M |
| CashFlowFromContinuingOperatingActivities | 27.37M | 141.58M | -47.20M | -35.38M |
| ChangeInWorkingCapital | 18.82M | 45.76M | -72.12M | -31.70M |
| ChangeInOtherWorkingCapital | -219.00K | -730.00K | -596.00K | -1.89M |
| ChangeInPayablesAndAccruedExpense | -14.02M | -30.36M | 4.00M | 6.52M |
| ChangeInAccruedExpense | -6.44M | -3.38M | 1.37M | 3.29M |
| ChangeInPayable | -7.58M | -26.98M | 2.63M | 3.23M |
| ChangeInAccountPayable | -7.58M | -26.98M | 2.63M | 3.23M |
| ChangeInPrepaidAssets | 4.09M | -2.50M | -7.09M | -8.67M |
| ChangeInInventory | 13.10M | 48.23M | -43.27M | -21.21M |
| ChangeInReceivables | 15.87M | 31.12M | -25.16M | -6.45M |
| ChangesInAccountReceivables | 15.87M | 31.12M | -25.16M | -6.45M |
| OtherNonCashItems | 22.00K | -67.00K | -94.00K | -1.54M |
| StockBasedCompensation | 11.92M | 10.73M | 11.62M | 7.81M |
| ProvisionandWriteOffofAssets | 71.00K | -462.00K | -1.03M | -253.00K |
| AssetImpairmentCharge | 4.39M | 10.83M | 17.10M | 0.00 |
| DeferredTax | -657.00K | 102.00K | -1.65M | 1.03M |
| DeferredIncomeTax | -657.00K | 102.00K | -1.65M | 1.03M |
| DepreciationAmortizationDepletion | 10.31M | 20.94M | 15.54M | 12.49M |
| DepreciationAndAmortization | 10.31M | 20.94M | 15.54M | 12.49M |
| AmortizationCashFlow | -564.00K | 3.00K | 228.00K | 837.00K |
| AmortizationOfIntangibles | -564.00K | 3.00K | 228.00K | 837.00K |
| Depreciation | 10.87M | 20.94M | 15.31M | 11.66M |
| OperatingGainsLosses | 2.00M | 103.00K | 568.00K | -210.00K |
| EarningsLossesFromEquityInvestments | 1.70M | 0.00 | 0.00 | |
| NetForeignCurrencyExchangeGainLoss | -263.00K | 103.00K | -161.00K | -210.00K |
| GainLossOnSaleOfPPE | 563.00K | 0.00 | 729.00K | 0.00 |
| GainLossOnSaleOfBusiness | 0.00 | 0.00 | ||
| NetIncomeFromContinuingOperations | -19.50M | 53.66M | -17.13M | -23.00M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for OSUR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|